OTCMKTS:GSTC GlobeStar Therapeutics (GSTC) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free GSTC Stock Alerts $0.0009 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.0009▼$0.000950-Day Range N/A52-Week Range$0.0006▼$0.0082Volume230,060 shsAverage Volume11.60 million shsMarket Capitalization$1.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get GlobeStar Therapeutics alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About GlobeStar Therapeutics Stock (OTCMKTS:GSTC)GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.Read More GSTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSTC Stock News HeadlinesMarch 28, 2024 | finanznachrichten.deGlobeStar Therapeutics Corporation: Globestar Therapeutics Update on Project Amethyst and Recent FinancialsDecember 20, 2023 | seekingalpha.comKHTRF Knight Therapeutics Inc.April 24, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.December 14, 2023 | morningstar.comGlobeStar Therapeutics Corp GSTCNovember 4, 2023 | msn.comGlobeStar signs deal with Advanced Innovative to develop clinical studies for MS treatmentNovember 2, 2023 | finance.yahoo.comGlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis TreatmentOctober 2, 2023 | benzinga.comPenny Stocks On The Move: HALB, NHMD, IFUS, GSTCSeptember 28, 2023 | finance.yahoo.comGlobestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis TreatmentApril 24, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.June 14, 2023 | finance.yahoo.comGlobestar Therapeutics Enters into MOU with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis TreatmentJanuary 3, 2023 | finance.yahoo.comGlobeStar Therapeutics Corporation (GSTC)November 27, 2022 | reuters.comGlobeStar Therapeutics CorpAugust 2, 2022 | finance.yahoo.comGlobeStar Therapeutics Corporation Update on Recent ActivityMarch 1, 2022 | finance.yahoo.comGlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking ContractMarch 1, 2022 | finance.yahoo.comCORRECTING and REPLACING GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking ContractFebruary 4, 2022 | finance.yahoo.comGlobeStar Therapeutics Corporation Addresses the Potential Link Between Neurodegenerative Disease and Parkinson’s DiseaseJanuary 12, 2022 | nasdaq.comGlobeStar Therapeutics Corp (GSTC)October 18, 2021 | finance.yahoo.comGlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All SeasonOctober 18, 2021 | finance.yahoo.comGlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding CampaignOctober 18, 2021 | finance.yahoo.comGlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple SclerosisOctober 18, 2021 | finance.yahoo.comGlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.October 18, 2021 | finance.yahoo.comGlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC MarketsSee More Headlines Receive GSTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlobeStar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:GSTC CUSIPN/A CIK1502152 Webangiosoma.com Phone(206) 451-1970FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,950,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-75,007.21% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,162,920,000Free Float1,133,848,000Market Cap$1.05 million OptionableNot Optionable Beta1.49 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. James C. Katzaroff (Age 67)President, CEO, Secretary, Principal Executive Officer & Chairman of the Board Comp: $180kMr. Robert R. Hale Chicoski CPA (Age 81)CFO, Treasurer, Secretary, Principal Financial & Accounting Officer Comp: $84kMs. Brooke GreenwaldChief Marketing OfficerMr. David CroomExecutive Vice PresidentKey CompetitorsSciSparcNASDAQ:SPRCNexien BioPharmaOTCMKTS:NXENNeptune Wellness SolutionsNASDAQ:NEPTBiodexa PharmaceuticalsNASDAQ:BDRXBaudax BioNASDAQ:BXRXView All Competitors GSTC Stock Analysis - Frequently Asked Questions How have GSTC shares performed in 2024? GlobeStar Therapeutics' stock was trading at $0.0009 on January 1st, 2024. Since then, GSTC stock has increased by 0.0% and is now trading at $0.0009. View the best growth stocks for 2024 here. Are investors shorting GlobeStar Therapeutics? GlobeStar Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 158,500 shares, a decrease of 35.0% from the March 15th total of 243,700 shares. Based on an average trading volume of 18,037,500 shares, the short-interest ratio is currently 0.0 days. View GlobeStar Therapeutics' Short Interest. How do I buy shares of GlobeStar Therapeutics? Shares of GSTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GSTC) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlobeStar Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
